Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma SA (IPHA) is a clinical-stage biotechnology leader advancing immuno-oncology therapies through innovative antibody development. This page serves as the definitive source for official company announcements and curated news coverage.
Key updates include clinical trial milestones, regulatory developments, strategic collaborations, and scientific advancements. Investors and researchers will find timely information on NK cell engager therapeutics, partnership expansions with major biopharma entities, and progress across the company's oncology pipeline.
All content is sourced directly from verified corporate communications and reputable financial analysis. Bookmark this page for streamlined access to IPHA's latest developments in harnessing innate immunity for cancer treatment breakthroughs.
Innate Pharma (Nasdaq: IPHA) will host an analyst and investor event on October 28, 2025 from 8:00–10:00 a.m. ET (1:00–3:00 p.m. CET) in New York and virtually to discuss lacutamab.
The program includes clinical perspectives on the TELLOMAK Phase 2 trial from KOL Pierluigi Porcu, M.D., real‑world U.S. CTCL population analysis from ZS Associates, and management updates on the planned Phase 3 trial, the regulatory pathway in CTCL with a path to potential accelerated approval in Sézary syndrome, and the commercial opportunity for lacutamab.
Live Q&A will be offered, registration is available for in‑person or virtual attendance, and a replay will be posted in the company’s investor relations section.
Innate Pharma (NASDAQ:IPHA) reported its H1 2025 business update and financial results, highlighting significant progress in its clinical pipeline. The company announced a strategic restructuring, including a 30% workforce reduction and prioritization of key clinical assets: IPH4502, lacutamab, and monalizumab.
Key developments include FDA Breakthrough Therapy Designation for lacutamab in February 2025, progression of IPH4502 Nectin-4 ADC Phase 1 enrollment, and completion of AstraZeneca's Phase 3 PACIFIC-9 enrollment for monalizumab. The company secured a €15 million equity investment from Sanofi in April 2025.
Financial position shows cash of €70.4 million as of June 30, 2025, with runway until Q3-2026. Revenue decreased to €4.9 million in H1 2025 from €12.3 million in H1 2024. Management changes include Eric Vivier's departure as CSO and Yannis Morel assuming CSO responsibilities.
Innate Pharma (NASDAQ:IPHA) announced its participation in the upcoming 25th European Midcap Event in Paris, France. The company's Chief Financial Officer, Frédéric Lombard, will represent Innate at the event, which takes place from September 30 to October 1, 2025.
The European Midcap Event serves as a strategic platform for institutional investors and listed companies to engage in meetings and explore financing opportunities within the European financial community.
Innate Pharma (NASDAQ:IPHA) has scheduled a conference call and webcast for Wednesday, September 17, 2025, at 2 p.m. CEST / 8 a.m. EDT to discuss its first half 2025 financial results and provide a business update.
Key executives participating in the call include CEO Jonathan Dickinson, CMO Sonia Quaratino, COO Yannis Morel, and CFO Frédéric Lombard. The presentation will be accessible via webcast and telephone, with a replay available on the company's website for 90 days following the event.
Innate Pharma (NASDAQ:IPHA) has disclosed its latest share capital and voting rights status as of September 1, 2025. The company reported 92,185,473 ordinary shares outstanding, along with 6,419 Preferred Shares 2016 and 7,581 Preferred Shares 2017.
The company's total theoretical voting rights stand at 92,962,943, while exercisable voting rights amount to 92,944,368. This disclosure is made in compliance with French regulatory requirements, including the French "Code de Commerce" and AMF regulations.
Innate Pharma (NASDAQ:IPHA) has released its updated share capital and voting rights information as of August 1, 2025. The company reported 92,184,823 ordinary shares outstanding, along with 6,424 Preferred Shares 2016 and 7,581 Preferred Shares 2017.
The company's total theoretical voting rights stand at 92,962,943, while exercisable voting rights amount to 92,944,368. This disclosure is made in compliance with French regulatory requirements and AMF recommendations.
Innate Pharma (NASDAQ:IPHA) announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025. The company's CEO Jonathan Dickinson and COO Yannis Morel will represent Innate at the event.
The company will participate in a Fireside chat on Wednesday July 30 at 2:00 PM EST, followed by one-on-one meetings. Notably, BTIG, which recently initiated analyst coverage of Innate Pharma, is hosting this conference as part of their global financial services offerings.
Innate Pharma (NASDAQ:IPHA) has disclosed its updated share capital and voting rights structure as of July 3, 2025. The company reported 92,183,523 ordinary shares outstanding, along with 6,434 Preferred Shares 2016 and 7,581 Preferred Shares 2017.
The total number of theoretical voting rights stands at 92,962,943, while exercisable voting rights amount to 92,944,368. This disclosure is made in compliance with French regulatory requirements and AMF recommendations.
FAQ
What is the current stock price of Innate Pharma Sa (IPHA)?
What is the market cap of Innate Pharma Sa (IPHA)?
